NeoGenomics (NASDAQ: NEO) net income
NeoGenomics reported a net loss of $108.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $78.7m.
NeoGenomics's best year of the last 10 was fiscal 2019. The biggest drop was in fiscal 2020, −47.9%. It reported a loss in 7 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin |
|---|---|---|---|
| 2025 | −$108.0m | — | −14.9% |
| 2024 | −$78.7m | — | −11.9% |
| 2023 | −$88.0m | — | −14.9% |
| 2022 | −$144.3m | — | −28.3% |
| 2021 | −$8.3m | −300.1% | −1.7% |
| 2020 | $4.2m | −47.9% | 0.9% |
| 2019 | $8.0m | +203.3% | 2.0% |
| 2018 | $2.6m | — | 1.0% |
| 2017 | −$0.4m | — | −0.2% |
| 2016 | −$6.1m | — | −2.6% |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
NeoGenomics net income compared with its sector
By net income for its latest fiscal year, NeoGenomics ranks 345th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of NeoGenomics, −14.9%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 343rd | AURA Biosciences | −$106.2m | — |
| 344th | Quanterix | −$107.2m | −77.1% |
| 345th | NeoGenomics | −$108.0m | −14.9% |
| 346th | Taysha Gene Therapies | −$109.0m | −1,115.3% |
| 347th | Rapport Therapeutics | −$111.5m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of NeoGenomics
- How much did NeoGenomics earn in fiscal 2025?
- NeoGenomics reported a net loss of $108.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $78.7m.
- What was the most profitable year for NeoGenomics?
- Of its last 10 fiscal years, fiscal 2019, with $8.0m.
- Where does NeoGenomics rank in its sector by net income?
- It ranks 345th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for NeoGenomics come from?
- From the annual report (Form 10-K) that NeoGenomics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that NeoGenomics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on NeoGenomics: the NeoGenomics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.